OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention

An update from OKYO Pharma Limited Sponsored ADR ( (OKYO) ) is now available.

On June 11, 2025, OKYO Pharma Limited announced that its CEO, Gary S. Jacob, Ph.D., will present at the Bio International Convention in Boston, MA, discussing the development of urcosimod, their lead clinical drug candidate for treating neuropathic corneal pain (NCP). Urcosimod, a lipid conjugated chemerin peptide agonist, has shown promising results in clinical trials, demonstrating anti-inflammatory and pain-reducing activities, and is currently being evaluated in a Phase 2 trial for NCP. This announcement highlights OKYO’s ongoing efforts to address severe ocular conditions and could enhance their positioning in the biopharmaceutical industry.

The most recent analyst rating on (OKYO) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on OKYO Pharma Limited Sponsored ADR stock, see the OKYO Stock Forecast page.

Spark’s Take on OKYO Stock

According to Spark, TipRanks’ AI Analyst, OKYO is a Underperform.

OKYO Pharma Limited’s stock is primarily affected by its significant financial challenges, including no revenue generation and negative equity. Technical analysis provides a neutral to slightly bearish outlook, while traditional valuation metrics are not applicable, reflecting typical biotech industry characteristics.

To see Spark’s full report on OKYO stock, click here.

More about OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropathic corneal pain and dry eye disease. The company is dedicated to discovering and developing novel molecules to treat these ocular conditions and has its ordinary shares listed on the NASDAQ Capital Market.

Average Trading Volume: 126,488

Technical Sentiment Signal: Buy

Current Market Cap: $70.14M

See more data about OKYO stock on TipRanks’ Stock Analysis page.